Showing 4591-4600 of 5771 results for "".
- Academy 2020 Moves Online Due to COVID-19https://modernod.com/news/academy-2020-moves-online-due-to-covid-19/2478154/As a direct result of the COVID-19 pandemic, the American Academy of Optometry’s (AAO) announced that Academy 2020 Nashville will be held entirely as a virtual meeting renamed Academy 2020 At Home. “We listened to our stakeholders and watched the national health situation very car
- Nicox Partners Zerviate in the Gulf and Arab Marketshttps://modernod.com/news/nicox-partners-zerviate-in-the-gulf-and-arab-markets/2478152/Nicox SA announced the signature of an exclusive license agreement with Itrom Pharmaceutical Group for the registration and commercialization of Zerviate (cetirizine ophthalmic solution), 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in Gulf and Arab markets. I
- Ocugen Receives Fourth FDA Orphan Drug Designation for Gene Therapy for the Treatment of Another Inherited Retinal Diseasehttps://modernod.com/news/ocugen-receives-fourth-fda-orphan-drug-designation-for-gene-therapy-for-the-treatment-of-another-inherited-retinal-disease/2478149/Ocugen announced the FDA granted the fourth Orphan Drug Designation (ODD) for OCU400 in the treatment of PDE6B gene mutation-associated retinal diseases. Retinitis Pigmentosa (RP) caused by PDE6B mutation is an inherited retinal dystrophy that leads to blindness by midlife and
- VSY Biotechnology Launches Enova Glistening-Free Hydrophobic Acrylic IOLhttps://modernod.com/news/vsy-biotechnology-launches-enova-glistening-free-hydrophobic-acrylic-iol/2478147/VSY Biotechnology announces the launch of the Enova IOL. Enova is the first 100% glistening-free hydrophobic acrylic IOL that does not require pre-hydration or storage in saline solution, according to VSY Biotechnology. The unique composition of Enova material allows uniform hydration of s
- Health Canada Approves Bausch + Lomb Ultra One Day Silicone Hydrogel Daily Disposable Contact Lenseshttps://modernod.com/news/health-canada-approves-bausch-lomb-ultra-one-day-silicone-hydrogel-daily-disposable-contact-lenses/2478142/Bausch + Lomb announced that it has received approval from Health Canada for the sale of Bausch + Lomb Ultra One Day daily disposable silicone hydrogel (SiHy daily) contact lenses. Bausch + Lomb Ultra One Day contact lenses feature a next generation contact lens material (kalifilcon A) wit
- AAO: Planned Medicare Cuts Deal Heavy Blow to Nation’s Ophthalmologistshttps://modernod.com/news/aao-planned-medicare-cuts-deal-heavy-blow-to-nations-ophthalmologists/2478132/The American Academy of Ophthalmology (AAO) released a statement opposing the Centers for Medicare & Medicaid Services (CMS) proposed annual Physician Fee Schedule and Quality Payment Program
- Bausch Health to Spin Off Eye Care Businesshttps://modernod.com/news/bausch-health-to-spin-off-eye-care-business/2478131/Bausch Health Companies announced Thursday that it intends to spin off its eye health business from its core pharmaceutical business into an independent publicly traded entity called Bausch + Lomb – NewCo. The spinoff will establish two separate companies—Bausch + Lomb- NewCo, a ful
- Bausch + Lomb Launches -2.75 Cylinder for Biotrue ONEday for Astigmatism Daily Disposable Contact Lenseshttps://modernod.com/news/bausch-lomb-launches-2-75-cylinder-for-biotrue-oneday-for-astigmatism-daily-disposable-contact-lenses/2478129/Bausch + Lomb announced the US launch of the -2.75 cylinder parameter offering for Biotrue ONEday for Astigmatism daily disposable contact lenses, the first and only toric daily disposable with a -2.75 cylinder. This new parameter offering will be available for same day fitting in a standard fit
- Palatin Technologies Completes Enrollment of Phase 2 Study for Dry Eye Disease Treatment Candidatehttps://modernod.com/news/palatin-technologies-announces-completion-of-enrollment-of-phase-2-study-with-pl9643-for-the-treatment-of-dry-eye-disease/2478124/Palatin Technologies announced completion of enrollment of its phase 2 study with PL9643 for the treatment of dry eye disease (DED). After delaying enrollment of new patient groups due to the COVID-19 pandemic, Palatin reinitiated enrollment in its PL9643 phase 2 clinical study in subjects
- Novavax Reports Positive Early Results for Experimental COVID-19 Vaccine NVX-CoV2373https://modernod.com/news/novavax-reports-positive-early-results-for-experimental-covid-19-vaccine-nvx-cov2373/2478122/Novavax announced preliminary data from a phase 1/2 study indicating that its recombinant coronavirus vaccine candidate NVX-CoV2373 triggered immune responses in healthy adults and was generally well-tolerated. According to findings in a paper, Novavax submitted to the preprint server medRxiv, th